BioMark Diagnostics Inc. BMKDF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.10K | 5.10K | 5.00K | 5.00K | 28.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.10K | 5.10K | 5.00K | 5.00K | 28.20K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.10K | 5.10K | 5.00K | 5.00K | 28.20K |
| SG&A Expenses | 115.70K | 79.20K | 155.50K | 149.00K | 144.40K |
| Depreciation & Amortization | 72.30K | 39.60K | 101.20K | 62.80K | 72.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 304.30K | 262.10K | 377.60K | 349.80K | 298.30K |
| Operating Income | -299.20K | -257.00K | -372.60K | -344.80K | -270.10K |
| Income Before Tax | -263.20K | -145.40K | -272.80K | -349.50K | -300.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -263.20K | -145.40K | -272.80K | -349.50K | -300.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -263.20K | -145.40K | -272.80K | -349.50K | -300.70K |
| EBIT | -299.20K | -257.00K | -372.60K | -344.80K | -270.10K |
| EBITDA | -296.10K | -254.00K | -369.70K | -341.90K | -267.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 106.36M | 105.09M | 105.09M | 105.09M | 105.09M |
| Average Diluted Shares Outstanding | 106.36M | 105.09M | 105.09M | 105.09M | 105.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |